Unbiased Analysis of Today's Healthcare Issues

Archive for January, 2018

To get our money’s worth in healthcare, we need to collaborate

This is the title of an interesting commentary in Modern Healthcare by my colleague Mark Linthicum. An excerpt is below. In healthcare, different stakeholders have vastly different perceptions of value, with important implications for decisionmaking. An employer paying for healthcare may want to find solutions that decrease employee absences and prevent lengthy hospitalizations. A health […]

Read the rest of this entry »

Medicaid and paperwork

When you buy a typical product, the vendor does its best to make the purchasing process as easy as possible.  There is a reason for this, clearly; they want your business.  State and federal governments, however, have no such incentive.  In fact, oftentimes reducing the number of people using government services saves money. Thus, it […]

Read the rest of this entry »

This month’s Health Wonk Review

Joe Paduda gets the year started with his  fresh edition of Health Wonk Review: Ring in the New year with the latest and greatest…posted at Managed Care Matters.  Check it out!  

Read the rest of this entry »

What is evidence-based health policy?

Many people have heard of evidence-based medicine (EBM).  A perspective piece in the New England Journal of Medicine by Katherine Baicker and Amitabh Chandra, however, tries to define what evidence-based health policy (EBHP) is.  They list three key criteria: Policies need to be well-specified.  For instance, “expand Medicaid coverage” is too general, whereas specifying that benefit package A […]

Read the rest of this entry »

Longitudinal Modelling of Healthcare Expenditures: Challenges and Solutions

Previous analyses–such as Basu and Manning 2009–have addressed the problem of mass of health care expenditures around $0. In typical economic analyses, we assume that the dependent variable is normally distributed. In the case of health care expenditures, however, a large number of people have $0 expenditures (i.e., healthy individuals). Further, among sick individuals that […]

Read the rest of this entry »

The gold standard of scientific evidence

That is the title of my latest article in Pharmaceutical Market Europe. An excerpt is below. Randomised controlled trials (RCTs) are regarded as the gold standard of scientific evidence, and for good reason. By randomizsing a treatment across study arms, RCTs eliminate patient-treamtent selection bias, resulting in reliable causal inference. In contrast, in the real […]

Read the rest of this entry »

Weekend Links

Words matter. 2017: Most drug approvals in 21 years. Digital medicine comes to your gut. “raising the level of discussion around value in health care” Spanish flu myths.

Read the rest of this entry »

Friday Links

Science facts from 2017. Peak pharma? 2017 year in charts. Nature’s 10. Physicians ignore an important source of data…the patient.  “If you don’t sit and talk with a patient for a half hour, in terms of your job description no one is going to be mad at you. But if you don’t know what the hemoglobin […]

Read the rest of this entry »

How does cost sharing rules influence drug prices in Germany?

Typically, we look at how changes in cost sharing affect patient demand.  However, rules regarding patient cost sharing also influence life sciences firms’ decisions about what price they should use for their products.  A paper by Herr and Suppliet (2017) looks at the effect of changing cost-sharing rules in Germany in their latest paper. The […]

Read the rest of this entry »

How did the Affordable Care Act affect the U.S. labor supply?

The Affordable Care Act (ACA) aimed to increase health insurance coverage largely through two pathways: (i) raising the income limits for individuals to qualify for Medicaid, (ii) creating new health insurance exchanges and health insurance subsidies to encourage the purchase of private health insurance among individuals that were not eligible for Medicaid.  Other provisions, such […]

Read the rest of this entry »